Amphastar Pharmaceuticals, Inc. (AMPH) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Madrigal Pharmaceuticals, Inc.

Prestige Consumer Healthcare, Inc.

Amicus Therapeutics, Inc.

Corcept Therapeutics, Inc.

Cytokinetics, Inc.

Ultragenyx Pharmaceutical, Inc.

Amphastar Pharmaceuticals, Inc.

Cerevel Therapeutics Holdings, Inc.

Akero Therapeutics, Inc.

MoonLake Immunotherapeutics

Bausch Health Cos., Inc.

Why is Amphastar Pharmaceuticals, Inc. ?

With a fall in PBT of -5.91%, the company declared Very Negative results in Sep 25

OPERATING CASH FLOW(Y) Lowest at USD 152.27 MM
ROCE(HY) Lowest at 14.84%
DEBTORS TURNOVER RATIO(HY) Lowest at 5.05 times

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -32.43% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Amphastar Pharmaceuticals, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Amphastar Pharmaceuticals, Inc.

-31.24%

-1.09

49.44%

S&P 500

13.68%

0.71

19.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

16.48%

EBIT Growth (5y)

79.71%

EBIT to Interest (avg)

32.30

Debt to EBITDA (avg)

0.53

Net Debt to Equity (avg)

0.50

Sales to Capital Employed (avg)

0.53

Tax Ratio

18.02%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

87.54%

ROCE (avg)

18.59%

ROE (avg)

15.73%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.34

EV to EBIT

9.18

EV to EBITDA

6.50

EV to Capital Employed

1.23

EV to Sales

1.90

PEG Ratio

Dividend Yield

ROCE (Latest)

13.44%

ROE (Latest)

14.12%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company

CASH AND EQV(HY)

Highest at USD 512.83 MM

DEBT-EQUITY RATIO (HY)

Lowest at 48.68 %

NET SALES(Q)

Highest at USD 191.84 MM

-26What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD 152.27 MM

ROCE(HY)

Lowest at 14.84%

DEBTORS TURNOVER RATIO(HY)

Lowest at 5.05 times

INTEREST COVERAGE RATIO(Q)

Lowest at 653.85

INVENTORY TURNOVER RATIO(HY)

Lowest at 2.41 times

OPERATING PROFIT(Q)

Lowest at USD 41.09 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 21.42 %

PRE-TAX PROFIT(Q)

Lowest at USD 21.51 MM

NET PROFIT(Q)

Lowest at USD 17.35 MM

EPS(Q)

Lowest at USD 0.36

Here's what is working for Amphastar Pharmaceuticals, Inc.

Net Sales

Highest at USD 191.84 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Cash and Eqv

Highest at USD 512.83 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at 48.68 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for Amphastar Pharmaceuticals, Inc.

Pre-Tax Profit

At USD 21.51 MM has Fallen at -48.55%

over average net sales of the previous four periods of USD 41.81 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD 17.35 MM has Fallen at -50.07%

over average net sales of the previous four periods of USD 34.75 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Interest Coverage Ratio

Lowest at 653.85

in the last five periods

MOJO Watch

The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Debtors Turnover Ratio

Lowest at 5.05 times and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Operating Cash Flow

Lowest at USD 152.27 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Operating Profit

Lowest at USD 41.09 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Operating Profit Margin

Lowest at 21.42 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at USD 21.51 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD 17.35 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

EPS

Lowest at USD 0.36

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Inventory Turnover Ratio

Lowest at 2.41 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio